BioMarin Pharma (BMRN) Tops Q2 EPS by 25c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 rises; Apple and Palantir set to report results
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $57.38 -1.93%
EPS Growth %: +1,025.0%
Financial Fact:
Interest income: 1.63M
Today's EPS Names:
LTBR, AES, SYRS, More
EPS Growth %: +1,025.0%
Financial Fact:
Interest income: 1.63M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of $1.20, $0.25 better than the analyst estimate of $0.95. Revenue for the quarter came in at $990 million versus the consensus estimate of $939.37 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rosenblatt keeps Buy rating on Marvell after Lumentum acquisition
- Upwork Inc. (UPWK) call put ratio 1 call to 1 put a share price up 8.3%
- Neogen Corp. (NEOG) spreader of 5K contracts of April 10 puts and April 15 calls
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
